GSK plc (GSK) Cash Flow Statement

The wide dispersion in OCF/NI suggests that net income is being distorted by non-cash items, timing effects, or non-recurring charges rather than reflecting steady underlying cash generation. The negative net income in 2024Q3 paired with positive operating cash flow of $2.2B illustrates how far reported earnings can diverge from cash reality. Analysts should treat headline net income with caution and anchor on multi-quarter operating cash flow instead.

Free cash flow has been positive in every reported quarter, which supports the view that the business is self-funding at the operating level. However, the margin range is too wide to extrapolate a reliable run-rate without normalizing for working capital swings. Investors may wish to monitor whether the strong 2025Q3 and 2026Q3 prints represent sustainable conversion or seasonal and one-off benefits.

The large reversals in working capital contributions suggest timing-driven collections and payables cycles, which may be linked to lumpy government vaccine tenders. Such patterns warrant further investigation into receivables and inventory levels, as they can mask underlying operating performance. Cumulative working capital over several quarters would provide a clearer read on true cash efficiency.

The higher capex intensity in 2025Q3 and 2025Q4 may reflect manufacturing expansion for biologics and vaccines, which is consistent with a high-fixed-cost production model. Depreciation and amortization of roughly $224M to $1.2B per quarter suggests that a portion of capex is replacing existing asset base. Distinguishing maintenance from growth capex would be necessary to judge whether current spending supports future volume or merely sustains it.

Dividend coverage appears adequate in most quarters, though the 2026Q1 and 2025Q1 periods show FCF of roughly $698M to $697M against payouts of about $643M to $612M, leaving limited headroom. Acquisition outflows, including a $7.1B figure in 2026Q3, suggest material bolt-on or portfolio investment that may constrain near-term cash accumulation. The balance between dividends and M&A warrants monitoring as the company reshapes its specialty pipeline.